熱門資訊> 正文
Kezar以每股1.10美元的价格收到Concentra的收购提案
2024-10-10 20:48
- Biotech company, Kezar Life Sciences (NASDAQ:KZR) said on Thursday that it has received an unsolicited, non-binding proposal from Concentra Biosciences, to acquire all the outstanding shares of Kezar for cash consideration of $1.10 per share.
- The proposal also includes a contingent value right that represents the right to receive 80% of the net proceeds from any out-license or disposition of Kezar’s development programs or intellectual property.
- Kezar (KZR) said its board and management team will carefully evaluate the non-binding proposal.
- The company’s shares rose more than 6% in pre-market trading on Thursday.
More on Kezar Life Sciences
- Kezar zetomipzomib IND for lupus placed on FDA clinical hold
- Seeking Alpha’s Quant Rating on Kezar Life Sciences
- Historical earnings data for Kezar Life Sciences
- Financial information for Kezar Life Sciences
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
